KRONOS BIO INC. - COM

0,9399

08-октября-24 15:59:58

15 мин. задержка

Акции

-0,0501

-5,06%

Сегодняшний диапазон

0,8520 - 0,9800

ISIN

N/A

Источник

NASDAQ

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

08 ноя 2021 16:44:44 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021

30 сен 2021 16:35:57 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations

14 сен 2021 08:00:02 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference

07 сен 2021 07:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results

12 авг 2021 16:05:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)

27 июл 2021 08:00:05 Источник Nasdaq GlobeNewswire
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today

25 май 2021 08:00:03 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

11 май 2021 16:05:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

06 май 2021 08:00:02 Источник Nasdaq GlobeNewswire
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021

10 апр 2021 08:30:00 Источник Nasdaq GlobeNewswire
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.

31 мар 2021 11:25:04 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors

26 мар 2021 08:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

23 мар 2021 16:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

10 мар 2021 16:35:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

04 мар 2021 07:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

25 фев 2021 08:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

26 янв 2021 08:00:02 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.